199 related articles for article (PubMed ID: 38227604)
1. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
Lin C; Xu G; Gao S; Feng T; Li S
Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
[TBL] [Abstract][Full Text] [Related]
3. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.
Stroh GR; Peikert T; Escalante P
Cancer Immunol Immunother; 2021 Nov; 70(11):3105-3111. PubMed ID: 33770211
[TBL] [Abstract][Full Text] [Related]
4. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
5. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.
Bae S; Kim YJ; Kim MJ; Kim JH; Yun SC; Jung J; Kim MJ; Chong YP; Kim SH; Choi SH; Kim YS; Lee SO
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34521732
[TBL] [Abstract][Full Text] [Related]
6. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.
Fujita K; Elkington P; Redelman-Sidi G; Kanai O; Yamamoto Y; Imakita T; Okamura M; Nakatani K; Mio T
Cancer Immunol Immunother; 2022 Nov; 71(11):2757-2764. PubMed ID: 35429244
[TBL] [Abstract][Full Text] [Related]
7. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
Kim HW; Kim JS; Lee SH
Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
10. Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Shimoda Y; Yoshida T; Miyakoshi J; Torasawa M; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2023 Aug; 72(8):2613-2621. PubMed ID: 37062033
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis.
He Y; Peng D; Liang P; Long J; Liu A; Zeng Z
J Clin Pharmacol; 2023 Apr; 63(4):397-409. PubMed ID: 36309847
[TBL] [Abstract][Full Text] [Related]
12. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
Im Y; Lee J; Kim SJ; Koh WJ; Jhun BW; Lee SH
Respir Med; 2020 Jan; 161():105853. PubMed ID: 32056727
[TBL] [Abstract][Full Text] [Related]
13. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
14. Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery.
Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
Oncology; 2024; 102(6):476-483. PubMed ID: 37984347
[TBL] [Abstract][Full Text] [Related]
15. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
Sun S; Liu C; Duan C; Yu S; Zhang Q; Xu N; Yu B; Wu X; Wang J; Hu X; Yu H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse.
Chandrashekara S; Panchagnula R; Chennupati Y
Rheumatology (Oxford); 2023 Dec; 62(12):3952-3956. PubMed ID: 37348542
[TBL] [Abstract][Full Text] [Related]
19. Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate.
Chen K; Jiang F; Zhou Q; Dong X; He T; Li Y; Luo Z; Duan W; Yang H
Ann Med; 2023; 55(2):2282182. PubMed ID: 38375813
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]